ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag european commission disease medicine immunology

Biopharma Looks to the Netherlands as European Hub
Jef Akst | Feb 1, 2021 | 7 min read
The recent move of the European Medicines Agency from London to Amsterdam is a reflection of the city’s vibrant life sciences and health sector and supporting industries.
aav adeno-associated virus vector gene therapy antibody hemophilia
Thwarting AAV-Neutralizing Antibodies Could Improve Gene Therapy
Emma Yasinski | Sep 25, 2020 | 5 min read
Adeno-associated viral vectors can deliver gene therapies, but AAV-neutralizing antibodies might prevent the medicines from working.
An Orphan Disease Gets Adopted
Steve Bunk | Nov 12, 2000 | 7 min read
Courtesy of Ed Rowton, Walter Reed Army Institute of Research An anopheline mosquito taking a blood meal. Researchers and physicians, open your guides to rare diseases, for that may be the only place you'll encounter Jumping Frenchmen of Maine. There you also will find Kabuki Make-up Syndrome, Split-Hand Deformity, Stiff Person Syndrome, Tangier Disease, and Twin-Twin Transfusion Syndrome. These are among thousands of "orphan diseases," originally so called because they weren't "adopted" by spon
2020 Top 10 Innovations
The Scientist | Dec 1, 2020 | 10+ min read
From a rapid molecular test for COVID-19 to tools that can characterize the antibodies produced in the plasma of patients recovering from the disease, this year’s winners reflect the research community’s shared focus in a challenging year.
How Some Vaccines Protect Against More than Their Targets
Shawna Williams | Nov 1, 2020 | 10+ min read
As researchers test existing vaccines for nonspecific protection against COVID-19, immunologists are working to understand how some inoculations protect against pathogens they weren’t designed to fend off.
Senior Scientists Quit Europe
Silvia Sanides | Jun 1, 2003 | 7 min read
©Paul Barton, Corbis Rigid retirement policies are prompting scientists to flee Europe at the height of their professional lives to start second careers in the United States. Many of these researchers are still conducting experiments and are in no mood to slow down. But because nearly all European universities are government run, professors are left little choice when they reach mandatory retirement age, which in most countries is 65 years or even younger. Some scientists leaving for the
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Week in Review: October 5–9
Tracy Vence | Oct 8, 2015 | 2 min read
This year’s Nobel Prizes; toward developing a brown fat-activating drug; certain antioxidants can increase the spread of melanoma in mice; anonymity and post-publication peer review
Fighting the 10/90 Gap
Ricki Lewis | May 12, 2002 | 5 min read
While wealthy nations pursue drugs to treat baldness and obesity, depression in dogs, and erectile dysfunction, elsewhere millions are sick or dying from preventable or treatable infectious and parasitic diseases.1 It's called the 10/90 gap. "Less than 10% of the worldwide expenditure on health research and development is devoted to the major health problems of 90% of the population," explains Els Torreele, co-chair of a working group that provided background recently for an initiative announced

Run a Search

ADVERTISEMENT